Zacks Investment Research cut shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine upgraded shares of Zafgen from a strong sell rating to a sell rating in a report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $6.38.
Zafgen (NASDAQ:ZFGN) opened at 3.46 on Friday. The company’s market cap is $95.09 million. Zafgen has a 52 week low of $2.89 and a 52 week high of $5.46. The company’s 50-day moving average is $3.46 and its 200-day moving average is $3.97.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. During the same quarter in the prior year, the business earned ($0.55) EPS. On average, analysts anticipate that Zafgen will post ($2.23) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/19/zacks-investment-research-downgrades-zafgen-inc-zfgn-to-hold-2.html.
In related news, insider Dennis D. Kim acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was acquired at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the acquisition, the insider now owns 21,443 shares of the company’s stock, valued at $72,691.77. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 21.20% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp raised its holdings in Zafgen by 5.9% in the 1st quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 5,794 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 10,327 shares in the last quarter. Paloma Partners Management Co raised its holdings in Zafgen by 17.4% in the 1st quarter. Paloma Partners Management Co now owns 130,000 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 19,278 shares in the last quarter. Algert Global LLC bought a new position in Zafgen in the 2nd quarter worth $123,000. Finally, Wells Fargo & Company MN raised its holdings in Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 40,400 shares in the last quarter. Institutional investors and hedge funds own 48.52% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.